<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="other" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Blood Purif</journal-id><journal-id journal-id-type="iso-abbrev">Blood Purif</journal-id><journal-id journal-id-type="pmc-domain-id">2985</journal-id><journal-id journal-id-type="pmc-domain">kargersd</journal-id><journal-id journal-id-type="publisher-id">BPU</journal-id><journal-title-group><journal-title>Blood Purification</journal-title></journal-title-group><issn pub-type="ppub">0253-5068</issn><issn pub-type="epub">1421-9735</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Karger Author's Choice</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12060816</article-id><article-id pub-id-type="pmcid-ver">PMC12060816.1</article-id><article-id pub-id-type="pmcaid">12060816</article-id><article-id pub-id-type="pmcaiid">12060816</article-id><article-id pub-id-type="pmid">40112784</article-id><article-id pub-id-type="doi">10.1159/000545120</article-id><article-id pub-id-type="publisher-id">545120</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Critical Care Nephrology</subject></subj-group></article-categories><title-group><article-title>In vitro Assessment of Drug Adsorption Profiles during Hemoadsorption Therapy</article-title><alt-title alt-title-type="short">Drug Removal by Hemoadsorption Therapy</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="relnr" authenticated="false">2778489</contrib-id><name name-style="western"><surname>K&#246;rtge</surname><given-names initials="A">Andreas</given-names></name><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="relnr" authenticated="false">2778490</contrib-id><name name-style="western"><surname>Kamper</surname><given-names initials="C">Christoph</given-names></name><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="relnr" authenticated="false">2778491</contrib-id><name name-style="western"><surname>Klinkmann</surname><given-names initials="G">Gerd</given-names></name><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>c</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="relnr" authenticated="false">2778492</contrib-id><name name-style="western"><surname>Wasserkort</surname><given-names initials="R">Reinhold</given-names></name><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="relnr" authenticated="false">2778493</contrib-id><name name-style="western"><surname>Mitzner</surname><given-names initials="S">Steffen</given-names></name><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref></contrib><aff id="aff1">
<label>a</label>Department of Extracorporeal Therapy Systems, Fraunhofer Institute for Cell Therapy and Immunology IZI, <city>Rostock</city>, <country>Germany</country></aff><aff id="aff2">
<label>b</label>Division of Nephrology, Center for Internal Medicine, Rostock University Medical Center, <city>Rostock</city>, <country>Germany</country></aff><aff id="aff3">
<label>c</label>Department of Anaesthesiology, Intensive Care Medicine and Pain Therapy, Rostock University Medical Center, <city>Rostock</city>, <country>Germany</country></aff></contrib-group><author-notes><corresp id="cor1">Correspondence to: Andreas K&#246;rtge, <email>andreas.koertge@izi.fraunhofer.de</email></corresp></author-notes><pub-date pub-type="epub"><day>20</day><month>3</month><year>2025</year></pub-date><pub-date pub-type="ppub"><month>7</month><year>2025</year></pub-date><volume>54</volume><issue>4-5</issue><issue-id pub-id-type="pmc-issue-id">488228</issue-id><fpage>218</fpage><lpage>225</lpage><history><date date-type="received"><day>21</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>3</day><month>3</month><year>2025</year></date><date date-type="subscription-year"><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>20</day><month>03</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>05</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-07-03 07:25:38.000"><day>03</day><month>07</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Author(s). Published by S. Karger AG, Basel</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This article is licensed under the Creative Commons Attribution 4.0 International License (CC BY) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.karger.com/Services/OpenAccessLicense">http://www.karger.com/Services/OpenAccessLicense</ext-link>). Usage, derivative works and distribution are permitted provided that proper credit is given to the author and the original publisher.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="bpu-2025-0054-04-5-545120.pdf"/><abstract><title>Abstract</title><sec><title>Introduction</title><p>The use of hemoadsorption devices is increasingly gaining impact as an adjunct therapy for various critical conditions in ICU patients, including systemic hyperinflammation, cytokine release syndrome, sepsis, and more. A key concern in this therapy is its impact on the plasma levels of concurrently administered drugs, which could potentially be reduced to subtherapeutic levels, affecting patient care. The present study investigates the adsorption behavior of various drugs in an in vitro hemoadsorption model using human whole blood, aiming to provide insights for optimizing drug dosing during hemoadsorption therapy.</p></sec><sec><title>Methods</title><p>The study assessed the removal rates and clearances of several drugs, namely, apixaban, argatroban, carbamazepine, oxcarbazepine, lamotrigine, phenytoin, valproate, levosimendan, methylene blue, and metformin, by circulating the blood through CytoSorb adsorbers in an in vitro setup.</p></sec><sec><title>Results</title><p>Significant removal (75 to 100% of the initial concentration) and high initial plasma clearances (approximately 10&#8211;25 mL/min) were observed for most of the tested drugs within the first 30&#8211;60 min of recirculation. Lower removal rates and clearances were noted for valproate (approximately 40% and 5 mL/min) and metformin (approximately 15% and 1 mL/min).</p></sec><sec><title>Conclusion</title><p>The findings indicate considerable differences in the adsorption of the tested drugs and should be confirmed by additional in vivo studies with careful monitoring of drug levels throughout the course of therapy. Understanding the in vivo dynamics is crucial for adjusting dosages appropriately during hemoadsorption use to ensure therapeutic efficacy and patient safety.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>Hemoadsorption</kwd><kwd>Drug removal</kwd><kwd>CytoSorb</kwd></kwd-group><funding-group><funding-statement>The study was financially supported by CytoSorbents Europe. Miniaturized adsorbers were provided by the company.</funding-statement></funding-group><counts><fig-count count="3"/><table-count count="1"/><ref-count count="38"/><page-count count="8"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="introduction" id="s1"><title>Introduction</title><p>Hemoadsorption is increasingly being recognized as an adjuvant therapy for various indications in critically ill patients, such as systemic hyperinflammation, cytokine release syndrome, sepsis, septic shock, acute kidney injury, and acute liver failure [<xref rid="B1" ref-type="bibr">1</xref>]. In the complex and critical environment of the intensive care unit, patients are frequently administered a multitude of pharmacological agents. Given the broad spectrum of medications used, it is imperative for clinicians to understand the effects of hemoadsorption on the plasma levels of these drugs. As with all other extracorporeal treatments, significant concern is that the hemoadsorption treatment could reduce the plasma concentrations of administered drugs to subtherapeutic levels, potentially compromising patient care. The implications of such interactions are not trivial; if drugs are strongly adsorbed, higher dosages might be necessary to sustain their therapeutic effects. Experimental studies using in vitro and animal models, as well as clinical investigations, have revealed that hemoadsorption can have a significant impact on the plasma levels and elimination rates of various drugs, including anticonvulsants [<xref rid="B2" ref-type="bibr">2</xref>], anticoagulants [<xref rid="B3" ref-type="bibr">3</xref>&#8211;<xref rid="B5" ref-type="bibr">5</xref>], antimicrobials [<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B6" ref-type="bibr">6</xref>&#8211;<xref rid="B9" ref-type="bibr">9</xref>], and others [<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>]. More studies conducting pharmacokinetic investigations of drugs during hemoadsorption are summarized in recent comprehensive review articles [<xref rid="B12" ref-type="bibr">12</xref>&#8211;<xref rid="B14" ref-type="bibr">14</xref>]. The actual degree of drug removal in patients is influenced by multiple factors such as drug-sorbent interaction, the presence of competing solutes, protein binding, volume of distribution (VOD), and patient-specific variables that may affect protein binding and endogenous clearance. Moreover, hemoadsorption is often used in combination with renal replacement therapies such as continuous venovenous hemofiltration (CVVH) or hemodialysis (HD) that can contribute to drug clearance as well. This not only poses challenges in clinical management but also underscores the necessity for careful monitoring of drugs prone to adsorption during hemoadsorption treatment. Various drugs relevant in the management of critical care patients were so far not sufficiently investigated with regard to their potential removal by hemoadsorption. To address this critical gap in knowledge, the present study aimed to elucidate the adsorption behavior of various drugs for which only limited data are available to date using an in vitro hemoadsorption model with human whole blood.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2-1"><title>Investigated Drugs</title><p>The drugs tested in the present study with their respective drug class, therapeutic range, target plasma concentration in the in vitro circulation, and VOD are listed in <xref rid="T1" ref-type="table">Table 1</xref>. The initial target plasma concentrations were oriented toward the therapeutic plasma levels of the respective drug. The selection of drugs was based on their clinical relevance and their potential role in critical care settings where CytoSorb might be integrated into the treatment regimen. These drugs were specifically chosen because their administration is not typically titrated by effect, presenting unique challenges in clinical practice. Furthermore, they were selected to address critical scenarios such as iatrogenic or suicidal overdoses, where their potential removal by the device could play a vital role in patient outcomes. The choice was informed by an analysis of potential gaps in the safety portfolio of the CytoSorb device.</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1.</label><caption><p>List of tested drugs with the respective drug class, therapeutic peak plasma concentration, target starting concentration, and VOD</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Drug</th><th rowspan="1" colspan="1">Drug class</th><th rowspan="1" colspan="1">Therapeutic peak plasma concentration</th><th rowspan="1" colspan="1">Target starting concentration</th><th rowspan="1" colspan="1">VOD, L/kg</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Argatroban</td><td rowspan="1" colspan="1">Anticoagulant</td><td rowspan="1" colspan="1">Argatroban in intensive care and cardiosurgical HIT patients (dose 0.5&#8211;2.5 &#181;g/kg/min [<xref rid="B15" ref-type="bibr">15</xref>]): &#8764;500&#8211;1,000 ng/mL [<xref rid="B16" ref-type="bibr">16</xref>]</td><td rowspan="1" colspan="1">1 &#181;g/mL</td><td rowspan="1" colspan="1">0.1795 [<xref rid="B16" ref-type="bibr">16</xref>]</td></tr><tr><td rowspan="3" colspan="1">Apixaban</td><td rowspan="3" colspan="1">Direct oral anticoagulant</td><td rowspan="1" colspan="1">Prevention of VTE (2.5 mg BID): 77 ng/mL (41, 146) [<xref rid="B17" ref-type="bibr">17</xref>]</td><td rowspan="3" colspan="1">150 ng/mL</td><td rowspan="3" colspan="1">0.2722 [<xref rid="B18" ref-type="bibr">18</xref>]</td></tr><tr><td rowspan="1" colspan="1">Prevention of stroke and systemic embolism (5 mg BID): 171 ng/mL (91, 321) [<xref rid="B17" ref-type="bibr">17</xref>]</td></tr><tr><td rowspan="1" colspan="1">Treatment of VTE and prevention of recurrent VTE (5 mg BID: 132 ng/mL (59, 302) [<xref rid="B17" ref-type="bibr">17</xref>]</td></tr><tr><td rowspan="1" colspan="1">Carbamazepine</td><td rowspan="1" colspan="1">Anticonvulsant</td><td rowspan="1" colspan="1">3&#8211;12 mg/L [<xref rid="B19" ref-type="bibr">19</xref>]</td><td rowspan="1" colspan="1">10 mg/L</td><td rowspan="1" colspan="1">0.79&#8211;1.4 [<xref rid="B20" ref-type="bibr">20</xref>]</td></tr><tr><td rowspan="1" colspan="1">Lamotrigine</td><td rowspan="1" colspan="1">Anticonvulsant</td><td rowspan="1" colspan="1">Therapeutic range: 3&#8211;14 mg/L [<xref rid="B21" ref-type="bibr">21</xref>]</td><td rowspan="1" colspan="1">15 mg/L</td><td rowspan="1" colspan="1">0.9&#8211;1.3 [<xref rid="B22" ref-type="bibr">22</xref>]</td></tr><tr><td rowspan="1" colspan="1">Oxcarbazepine</td><td rowspan="1" colspan="1">Anticonvulsant</td><td rowspan="1" colspan="1">Therapeutic range: 15&#8211;35 mg/L [<xref rid="B23" ref-type="bibr">23</xref>]</td><td rowspan="1" colspan="1">20 mg/L</td><td rowspan="1" colspan="1">3.9&#8211;12.5 [<xref rid="B23" ref-type="bibr">23</xref>]</td></tr><tr><td rowspan="1" colspan="1">Phenytoin</td><td rowspan="1" colspan="1">Anticonvulsant</td><td rowspan="1" colspan="1">Therapeutic range: 5&#8211;20 mg/L [<xref rid="B24" ref-type="bibr">24</xref>]</td><td rowspan="1" colspan="1">20 mg/L</td><td rowspan="1" colspan="1">0.75 [<xref rid="B25" ref-type="bibr">25</xref>]</td></tr><tr><td rowspan="1" colspan="1">Valproate</td><td rowspan="1" colspan="1">Anticonvulsant</td><td rowspan="1" colspan="1">Therapeutic range: 50&#8211;100 mg/L [<xref rid="B24" ref-type="bibr">24</xref>]</td><td rowspan="1" colspan="1">100 mg/L</td><td rowspan="1" colspan="1">0.1&#8211;0.4 [<xref rid="B26" ref-type="bibr">26</xref>]</td></tr><tr><td rowspan="1" colspan="1">Levosimendan</td><td rowspan="1" colspan="1">Calcium sensitizer</td><td rowspan="1" colspan="1">Congestive heart failure, observed range in clinical studies: &#8764;10&#8211;100 ng/mL [<xref rid="B27" ref-type="bibr">27</xref>]</td><td rowspan="1" colspan="1">35 ng/mL</td><td rowspan="1" colspan="1">0.3 [<xref rid="B28" ref-type="bibr">28</xref>]</td></tr><tr><td rowspan="1" colspan="1">Metformin</td><td rowspan="1" colspan="1">Oral hypoglycemic agent</td><td rowspan="1" colspan="1">0.1&#8211;2.5 mg/L [<xref rid="B29" ref-type="bibr">29</xref>]</td><td rowspan="1" colspan="1">1 mg/L</td><td rowspan="1" colspan="1">0.432&#8211;0.856 [<xref rid="B30" ref-type="bibr">30</xref>]</td></tr><tr><td rowspan="1" colspan="1">Methylene blue</td><td rowspan="1" colspan="1">Antidote</td><td rowspan="1" colspan="1">Rescue treatment for various indications (dose 1&#8211;2 mg/kg IV [<xref rid="B31" ref-type="bibr">31</xref>]): &#8764;10 &#181;mol/L = 3 &#181;g/mL [<xref rid="B32" ref-type="bibr">32</xref>]</td><td rowspan="1" colspan="1">3 mg/L</td><td rowspan="1" colspan="1">0.222&#8211;0.867 [<xref rid="B33" ref-type="bibr">33</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>Apixaban concentrations taken from reference [<xref rid="B17" ref-type="bibr">17</xref>] are given as median (5th, 95th percentile).</p></fn><fn><p>HIT, heparin-induced thrombocytopenia; VTE, venous thromboembolism; BID, twice daily; IV, intravenous.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-2"><title>Experimental Setup and Test Procedure</title><p>The test setup is shown in <xref rid="F1" ref-type="fig">Figure 1</xref>. The experiments were conducted with miniaturized versions (60 mL) of the CytoSorb<sup>&#174;</sup> hemadsorption column (CytoSorbents Europe, Berlin, Germany) in an in vitro circuit that was downscaled in a 1:5 ratio. One liter of citrate-anticoagulated human whole blood (Haema, Leipzig, Germany) mixed from two 500 mL blood donations of AB0-compatible donors was used as test solution. The blood was donated max. 24 h prior to each experiment and stored at 4&#176;C until start of the experiments. A blood pH value between 7.35 and 7.45 was adjusted by administration of 3 <sc>M</sc> Tris buffer solution (K&#246;hler Pharma, Alsbach-H&#228;hnlein, Germany) before the experiments. Immediately prior to commencing the experiment, the test blood was spiked with one of the drugs and the reservoir bag was gently agitated to ensure an even distribution. New fresh blood was used for each experiment.</p><fig position="float" id="F1" orientation="portrait"><label>Fig. 1.</label><caption><p>In vitro experimental setup.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="bpu-2025-0054-04-5-545120_F01.jpg"/></fig><p>Prior to circulation of the blood, both the miniaturized adsorber and the tubing were rinsed with physiological saline for a duration of 10 min using a roller pump (MCP Standard; Ismatec, Wertheim, Germany) at a flow rate of 40 mL/min. Subsequently, the blood was circulated for 5 h at the same flow rate of 40 mL/min. The blood was warmed to 37&#176;C with an infrared flow heater (Fluido<sup>&#174;</sup>; The Surgical Company, Kleve, Germany). During the experiments, pH was monitored and if necessary readjusted by administration of further Tris buffer solution every 30&#8211;60 min. Sedimentation of blood cells was prevented by gently agitating the reservoir bag with a rocking shaker throughout the experiment. All experiments were conducted in duplicate for each drug.</p></sec><sec id="s2-3"><title>Sampling and Laboratory Measurements</title><p>Blood samples (3 mL) were collected for measuring the concentrations of the drugs from the inlet (c<sub>in</sub>) and outlet sampling port (c<sub>out</sub>) at t = 0, 5, 15, 30, 60, 120, and 300 min. The samples were centrifuged immediately at 1,500 rcf for 10 min. To assess potential decay of the drugs during the test period, a control sample taken from the pool bag was kept in a water bath at 37&#176;C for 300 min and centrifuged after completion of the tests. The plasma supernatant was carefully collected from the centrifuged samples and stored at &#8722;20&#176;C until analysis.</p><p>Sampling for pH monitoring and adjustment was conducted at the beginning of the experiments and in intervals of 30 to 60 min during the test period (0.5 mL blood per sample). The pH was measured using a blood gas analyzer (ABL90 FLEX; Radiometer, Krefeld, Germany). The initial hematocrit in the pool bag was determined with an automated hematology analyzer (KX-21N; Sysmex, Kobe, Japan).</p><p>The concentrations of argatroban and apixaban were analyzed with a spectrophotometer (SPECORD 50 PLUS; Analytik Jena, Jena, Germany) using chromogenic anti-Factor Xa (BIOPHEN Heparin; HYPHEN BioMed, Neuville-sur-Oise, France) and anti-Factor IIa activity assays (BIOPHEN DTI; HYPHEN BioMed), respectively, and calibrators/controls of the respective analyte (HYPHEN BioMed). The anticonvulsants carbamazepine, lamotrigine, oxcarbazepine, and phenytoin were analyzed with high-performance liquid chromatography and a photodiode array detector using a commercial assay kit (ClinRep; RECIPE Chemicals and Instruments, Munich, Germany). Additional measurements were performed by an external laboratory (Medical Laboratory Bremen [MLHB]) using a liquid chromatography mass spectrometry (LC/MS) method.</p><p>Valproate was analyzed in the Central Laboratory of the Rostock University Medical Center using a chemiluminescent microparticle immunoassay. Levosimendan was analyzed using an LC/MS method. Metformin was analyzed by the MLHB using an LC/MS method. Methylene blue was analyzed photometrically (SPECORD 50 PLUS). The percentage removal was calculated as follows:<disp-formula id="ueq1"><mml:math id="m1" overflow="scroll"><mml:mrow><mml:mtext>removal</mml:mtext><mml:mspace width="0.25em"/><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mo>%</mml:mo></mml:mrow></mml:mfenced></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo></mml:mrow><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:msub><mml:mi mathvariant="normal">c</mml:mi><mml:mtext>in</mml:mtext></mml:msub><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mspace width="0.25em"/><mml:mi>min</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mo>&#8722;</mml:mo><mml:mspace width="0.25em"/><mml:msub><mml:mi mathvariant="normal">c</mml:mi><mml:mtext>in</mml:mtext></mml:msub><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mo>=</mml:mo><mml:mn>300</mml:mn><mml:mspace width="0.25em"/><mml:mi>min</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:mfenced></mml:mrow><mml:mo>/</mml:mo><mml:msub><mml:mi mathvariant="normal">c</mml:mi><mml:mtext>in</mml:mtext></mml:msub><mml:mrow><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mspace width="0.25em"/><mml:mi>min</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mi mathvariant="normal">&#215;</mml:mi><mml:mn>100</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula>with the concentrations of the respective drug at the inlet of the adsorber at the start (c<sub>in</sub>(t = 0 min)) and the end of the experiments (c<sub>in</sub>(t = 300 min)). The plasma clearance CL was calculated as follows:<disp-formula id="ueq2"><mml:math id="m2" overflow="scroll"><mml:mrow><mml:mtext>CL</mml:mtext><mml:mspace width="0.25em"/><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mtext>mL</mml:mtext><mml:mo>/</mml:mo><mml:mi>min</mml:mi><mml:mo>&#8289;</mml:mo></mml:mrow></mml:mfenced></mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mi mathvariant="normal">Q</mml:mi><mml:mi mathvariant="normal">B</mml:mi></mml:msub><mml:mi mathvariant="normal">&#215;</mml:mi><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#8722;</mml:mo><mml:mtext>Hct</mml:mtext></mml:mrow></mml:mfenced></mml:mrow><mml:mi mathvariant="normal">&#215;</mml:mi><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:msub><mml:mi mathvariant="normal">c</mml:mi><mml:mtext>in</mml:mtext></mml:msub><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mo>&#8722;</mml:mo><mml:msub><mml:mi mathvariant="normal">c</mml:mi><mml:mtext>out</mml:mtext></mml:msub><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:mfenced></mml:mrow><mml:mo>/</mml:mo><mml:msub><mml:mi mathvariant="normal">c</mml:mi><mml:mtext>in</mml:mtext></mml:msub><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math></disp-formula>with the flow rate Q<sub>B</sub> and the hematocrit of the test blood Hct.</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><p>The concentration-time curves obtained in the in vitro adsorption experiments for the tested substances are presented in <xref rid="F2" ref-type="fig">Figure 2</xref>a&#8211;j. Except for metformin (<xref rid="F2" ref-type="fig">Fig. 2</xref>f) and valproate (<xref rid="F2" ref-type="fig">Fig. 2</xref>j), the substances are considerably removed within the first 30&#8211;60 min of recirculation through the adsorber.</p><fig position="float" id="F2" orientation="portrait"><label>Fig. 2.</label><caption><p>Concentration-time curves determined at the inlet and outlet of the miniaturized CytoSorb cartridges during 300 min of recirculation for apixaban (<bold>a</bold>), argatroban (<bold>b</bold>), carbamazepine (<bold>c</bold>), lamotrigine (<bold>d</bold>), levosimendan (<bold>e</bold>), metformin (<bold>f</bold>), methylene blue (<bold>g</bold>), oxcarbazepine (<bold>h</bold>), phenytoin (<bold>i</bold>), and valproate (<bold>j</bold>) (mean &#177; SD, <italic toggle="yes">n</italic> = 2). The respective starting concentration (inlet concentration at t = 0 min) and outlet concentration at 60 min are indicated by arrows.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="bpu-2025-0054-04-5-545120_F02.jpg"/></fig><p>The total removal after 300 min is shown in <xref rid="F3" ref-type="fig">Figure 3</xref> a. Here, the substances are sorted by percentage removal from high to low. For levosimendan, oxcarbazepine, apixaban, phenytoin, lamotrigine, argatroban, carbamazepine, and methylene blue removal rates between 75 and 100% were observed, while only approximately 40% and 15% of the initial boluses of valproate and metformin, respectively, were removed. Accordingly, the corresponding clearances averaged over the time points between 5 and 30 min (<xref rid="F3" ref-type="fig">Fig. 3</xref>b) are high (10&#8211;25 mL/min) for substances with strong removal and low for valproate (5 mL/min) and metformin (&#8764;1 mL/min). The comparatively low clearance for carbamazepine is due to the small difference in inlet and outlet concentrations after 30 min (the actual outlet concentration is lower than the lower limit of quantification of the analytical method).</p><fig position="float" id="F3" orientation="portrait"><label>Fig. 3.</label><caption><p>
<bold>a</bold> Percentage removal of the tested drugs after 300 min of recirculation of the test blood through the miniaturized CytoSorb cartridges (mean &#177; SD, <italic toggle="yes">n</italic> = 2). <bold>b</bold> Mean clearances (averaged from the clearances calculated at 5, 15, and 30 min). *For carbamazepine, the clearances at 30 min were excluded from the mean clearance value because the outlet concentration values were incorrectly high (equal to the LOD of the analytical method) yielding an underestimated clearance.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="bpu-2025-0054-04-5-545120_F03.jpg"/></fig></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>The precise dosing of medication is of great importance, especially in intensive care medicine. Overdosing and, above all, underdosing can lead to severe side effects and contribute to an unfavorable prognosis including death in the patients concerned. In this context, the most comprehensive possible knowledge of drug removal by direct hemoadsorption procedures is of great clinical importance. Extensive findings are already available in this context, particularly for the use of the CytoSorb adsorber. However, information on various drugs relevant to critical care medicine has so far been lacking. Therefore, the current study investigated the removal of various drugs during hemoadsorption using the CytoSorb cartridge in an in vitro setting with human whole blood. With the exception of valproate and metformin, all tested drugs were significantly removed within the first 60 min of circulation through the adsorber. The rapid clearance of the solutes within the initial minutes was in accordance with observations from other in vitro studies investigating the removal of anticoagulants [<xref rid="B3" ref-type="bibr">3</xref>&#8211;<xref rid="B5" ref-type="bibr">5</xref>], anticonvulsants [<xref rid="B2" ref-type="bibr">2</xref>], and antimicrobials [<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B7" ref-type="bibr">7</xref>&#8211;<xref rid="B9" ref-type="bibr">9</xref>]. In these studies, the majority of the drug clearance likewise occurred within the first 60 min.</p><p>However, our findings were generated with a one-compartment in vitro setup and due to limited transferability to the multi-compartment in vivo setting do not necessarily reflect the extent of changes in drug levels in patients as a result of the hemoadsorption treatment. For drugs with a small VOD equivalent to the intravascular volume, in vivo removal should be reasonably accurately modeled with the current in vitro model. However, for drugs with a large VOD that are also distributed in intravascular fluid and in other body tissues, the in vitro model only reflects part of the reality. In addition, evaluating the clinical significance of potential drug removal requires considering several factors, including the patient&#8217;s specific medical condition especially liver and kidney function, co-medication, any concurrent extracorporeal therapies, the duration of device use, and whether the drug has just been administered or has reached steady-state levels in the patient&#8217;s system. Since hemoadsorption primarily targets hydrophobic substances that are typically protein-bound, other influencing factors besides the VOD, such as protein binding and affinity, must be considered when assessing the impact of these devices on drug levels. Due to these factors, while in vitro drug removal data are informative, they may not be directly applicable to more complex in vivo conditions. In vitro data therefore represent a &#8220;worst-case&#8221; scenario of drug removal, meaning that removal in vivo will be maximally the same but not higher. With regard to our findings, this means that for valproate and metformin a clinically significant removal by hemoadsorption using the CytoSorb device under in vivo conditions seems unlikely, whereas for the other tested substances a relevant elimination should be expected or at least cannot be excluded. It is important to note that in clinical practice hemoadsorption devices are often used in combination with other blood purification methods, such as CVVH or HD. Clinical experience indicates that both metformin and valproate can be effectively removed through CVVH and HD [<xref rid="B34" ref-type="bibr">34</xref>&#8211;<xref rid="B37" ref-type="bibr">37</xref>]. This should be considered when applying hemoadsorption in combination with filter-based blood purification methods.</p><p>Another limitation is that the experiment is a one-compartment model without &#8220;refill&#8221; conditions. For substances with high removal efficiency, the actual performance of the removal process cannot be accurately evaluated because the substance is depleted from the circuit in a short time, leaving no more substance to measure.</p><p>While drug removal by hemoadsorption or any other extracorporeal treatment is usually considered to be an unwanted effect, hemoadsorption might also be beneficial in case of unintentional drug overdose or intoxication as a suicidal attempt. A recent review summarizes case reports on the use of CytoSorb in these indications [<xref rid="B38" ref-type="bibr">38</xref>]. Drugs reported on include beta blockers, antihypertensives, antidepressants, antiarrhythmic, antipsychotics, anticonvulsants, and MDMA (ecstasy). It is noted that for many substances there are no known reversal agents or antidotes. Hence, the use of CytoSorb was considered a therapeutic option, especially considering its strong safety profile and the emergency of these life-threatening situations.</p><p>In conclusion, this in vitro study on hemoadsorption has demonstrated significant variability in the removal rates of different drugs when using the CytoSorb device. Similar as in other extracorporeal treatments, for drugs prone to removal also hemoadsorption treatment can potentially have a marked impact on plasma concentrations in patients, necessitating careful consideration of drug-specific adsorption properties. Understanding these properties and also the pertaining limitations of in vitro results is crucial for optimizing drug dosing strategies in clinical settings where hemoadsorption is employed. By refining dosing regimens based on the adsorption characteristics observed in this study, clinicians can better maintain therapeutic drug levels, thereby enhancing the effectiveness of the CytoSorb therapy and potentially improving patient outcomes. Future in vivo studies with close monitoring of drug levels during and after hemoadsorption are warranted to validate these in vitro observations and further guide clinical practice.</p></sec><sec sec-type="acknowledgments" id="s5"><title>Acknowledgments</title><p>The authors gratefully acknowledge excellent experimental work by Jenny Kristmann and the contributions of Teresa Klaus and Joerg Scheier to the preparation of the manuscript.</p></sec><sec sec-type="statement of ethics" id="s6"><title>Statement of Ethics</title><p>This study was conducted with approval by the Freiburg Ethics Committee International (permit number 011/1763) and is in compliance with the principles of the Declaration of Helsinki. All subjects gave prior written informed consent for the scientific use of their blood.</p></sec><sec sec-type="COI-statement" id="s7"><title>Conflict of Interest Statement</title><p>G.K. received lecture honoraria from CytoSorbents Europe. S.M. received travel support and honoraria from CytoSorbents Europe for medical consultation. Apart from this, the authors have no conflicts of interest to declare.</p></sec><sec sec-type="funding sources" id="s8"><title>Funding Sources</title><p>The study was financially supported by CytoSorbents Europe. Miniaturized adsorbers were provided by the company.</p></sec><sec sec-type="author contributions" id="s9"><title>Author Contributions</title><p>Conceptualization: A.K., S.M., and R.W.; formal analysis, investigation, methodology, and validation: A.K. and C.K.; project administration, visualization, and writing &#8211; original draft: A.K.; resources and supervision: S.M. and R.W.; writing &#8211; review and editing: A.K., G.K., R.W., and S.M. All authors have read and agreed to the published version of the manuscript.</p></sec></body><back><sec sec-type="data-availability" id="s12"><title>Data Availability Statement</title><p>Data are contained within the article. Further inquiries can be directed to the corresponding author.</p></sec><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>K&#246;hler</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Schwier</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Praxenthaler</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kirchner</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Henzler</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Eickmeyer</surname><given-names>C</given-names></string-name></person-group>. <article-title>Therapeutic modulation of the host defense by hemoadsorption with CytoSorb&#174;-basics, indications and perspectives-A scoping review</article-title>. <source>Int J Mol Sci</source>. <year>2021</year>;<volume>22</volume>(<issue>23</issue>):<fpage>12786</fpage>.<pub-id pub-id-type="pmid">34884590</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms222312786</pub-id><pub-id pub-id-type="pmcid">PMC8657779</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Reiter</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Bordoni</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Dall&#8217;Olio</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Ricatti</surname><given-names>MG</given-names></string-name>, <string-name name-style="western"><surname>Soli</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ruperti</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>In vitro removal of therapeutic drugs with a novel adsorbent system</article-title>. <source>BPU</source>. <year>2002</year>;<volume>20</volume>(<issue>4</issue>):<fpage>380</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000063108</pub-id><pub-id pub-id-type="pmid">12169849</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Koertge</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wasserkort</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Wild</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Mitzner</surname><given-names>S</given-names></string-name></person-group>. <article-title>Extracorporeal hemoperfusion as a potential therapeutic option for critical accumulation of rivaroxaban</article-title>. <source>BPU</source>. <year>2018</year>;<volume>45</volume>(<issue>1&#8211;3</issue>):<fpage>126</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000484923</pub-id><pub-id pub-id-type="pmid">29402788</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>R&#248;ed-Undlien</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Schultz</surname><given-names>NH</given-names></string-name>, <string-name name-style="western"><surname>Lunnan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Husebr&#229;ten</surname><given-names>IM</given-names></string-name>, <string-name name-style="western"><surname>Wollmann</surname><given-names>BM</given-names></string-name>, <string-name name-style="western"><surname>Molden</surname><given-names>E</given-names></string-name>, <etal/></person-group>. <article-title>In vitro apixaban removal by CytoSorb whole blood adsorber: an experimental study</article-title>. <source>J Cardiothorac Vasc Anesth</source>. <year>2022</year>;<volume>36</volume>(<issue>6</issue>):<fpage>1636</fpage>&#8211;<lpage>44</lpage>.<pub-id pub-id-type="pmid">35272914</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.jvca.2022.01.038</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tripathi</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Morales</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Gibson</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Mack</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Schneider</surname><given-names>DJ</given-names></string-name>, <etal/></person-group>. <article-title>Antithrombotic drug removal from whole blood using Haemoadsorption with a porous polymer bead sorbent</article-title>. <source>Eur Heart J Cardiovasc Pharmacother</source>. <year>2022</year>;<volume>8</volume>(<issue>8</issue>):<fpage>847</fpage>&#8211;<lpage>56</lpage>.<pub-id pub-id-type="pmid">35657375</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ehjcvp/pvac036</pub-id><pub-id pub-id-type="pmcid">PMC9716861</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schneider</surname><given-names>AG</given-names></string-name>, <string-name name-style="western"><surname>Andr&#233;</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Scheier</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Schmidt</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ziervogel</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Buclin</surname><given-names>T</given-names></string-name>, <etal/></person-group>. <article-title>Pharmacokinetics of anti-infective agents during CytoSorb hemoadsorption</article-title>. <source>Sci Rep</source>. <year>2021</year>;<volume>11</volume>(<issue>1</issue>):<fpage>10493</fpage>.<pub-id pub-id-type="pmid">34006946</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-021-89965-z</pub-id><pub-id pub-id-type="pmcid">PMC8131695</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ram&#237;rez-Guerrero</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Reis</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Lorenzin</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Marcello</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>de Cal</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Zanella</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>Effect of mechanical vibration on kinetics of solute adsorption</article-title>. <source>BPU</source>. <year>2024</year>;<volume>53</volume>(<issue>6</issue>):<fpage>500</fpage>&#8211;<lpage>4</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000536412</pub-id><pub-id pub-id-type="pmid">38281478</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Biever</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Staudacher</surname><given-names>DL</given-names></string-name>, <string-name name-style="western"><surname>Sommer</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Triebel</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Neukamm</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Bode</surname><given-names>C</given-names></string-name>, <etal/></person-group>. <article-title>Hemoadsorption eliminates remdesivir from the circulation: implications for the treatment of COVID-19</article-title>. <source>Pharmacol Res Perspect</source>. <year>2021</year>;<volume>9</volume>(<issue>2</issue>):<fpage>e00743</fpage>.<pub-id pub-id-type="pmid">33710753</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/prp2.743</pub-id><pub-id pub-id-type="pmcid">PMC7953359</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>K&#246;nig</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>R&#246;hr</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Frey</surname><given-names>OR</given-names></string-name>, <string-name name-style="western"><surname>Brinkmann</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Roberts</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Wichmann</surname><given-names>D</given-names></string-name>, <etal/></person-group>. <article-title>In vitro removal of anti-infective agents by a novel cytokine adsorbent system</article-title>. <source>Int J Artif Organs</source>. <year>2019</year>;<volume>42</volume>(<issue>2</issue>):<fpage>57</fpage>&#8211;<lpage>64</lpage>.<pub-id pub-id-type="pmid">30545255</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0391398818812601</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>K&#246;rtge</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wasserkort</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Mitzner</surname><given-names>S</given-names></string-name></person-group>. <source>Final report: analysis of the retention characteristics of CytoSorb hemadsorption columns for drugs which are frequently used for intentional poisoning and additional substances</source>. <publisher-loc>Rostock</publisher-loc>: <publisher-name>Fraunhofer IZI/EXIM</publisher-name>; <year>2017</year>.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Leber</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Liebchen</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Rohrhofer</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Weber</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Klaus</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Scheier</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Pharmacokinetics of immunosuppressive agents during hemoperfusion in a sheep model</article-title>. <source>Front Med</source>. <year>2023</year>;<volume>10</volume>:<fpage>1258661</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmed.2023.1258661</pub-id><pub-id pub-id-type="pmcid">PMC10623319</pub-id><pub-id pub-id-type="pmid">37928476</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Furukawa</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Lankadeva</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Bellomo</surname><given-names>R</given-names></string-name></person-group>. <article-title>The impact of hemoadsorption on antimicrobials</article-title>. <source>J Transl Crit Care Med</source>. <year>2024</year>;<volume>6</volume>(<issue>3</issue>):<fpage>e24</fpage>.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Scheier</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Nelson</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Schneider</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Colombier</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kindgen-Milles</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Deliargyris</surname><given-names>EN</given-names></string-name>, <etal/></person-group>. <article-title>Mechanistic considerations and pharmacokinetic implications on concomitant drug administration during CytoSorb therapy</article-title>. <source>Crit Care Explor</source>. <year>2022</year>;<volume>4</volume>(<issue>5</issue>):<fpage>e0688</fpage>.<pub-id pub-id-type="pmid">35783552</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CCE.0000000000000688</pub-id><pub-id pub-id-type="pmcid">PMC9243242</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Berlot</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Di Bella</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Tomasini</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Roman-Pognuz</surname><given-names>E</given-names></string-name></person-group>. <article-title>The effects of hemoadsorption on the kinetics of antibacterial and antifungal agents</article-title>. <source>Antibiot</source>. <year>2022</year>;<volume>11</volume>(<issue>2</issue>):<fpage>180</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/antibiotics11020180</pub-id><pub-id pub-id-type="pmcid">PMC8868360</pub-id><pub-id pub-id-type="pmid">35203783</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Koster</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Fischer</surname><given-names>K-G</given-names></string-name>, <string-name name-style="western"><surname>Harder</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mertzlufft</surname><given-names>F</given-names></string-name></person-group>. <article-title>The direct thrombin inhibitor argatroban: a review of its use in patients with and without HIT</article-title>. <source>Biologics</source>. <year>2007</year>;<volume>1</volume>(<issue>2</issue>):<fpage>105</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="pmid">19707320</pub-id><pub-id pub-id-type="pmcid">PMC2721302</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Swan</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Hursting</surname><given-names>MJ</given-names></string-name></person-group>. <article-title>The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction</article-title>. <source>Pharmacotherapy</source>. <year>2000</year>;<volume>20</volume>(<issue>3</issue>):<fpage>318</fpage>&#8211;<lpage>29</lpage>.<pub-id pub-id-type="pmid">10730687</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1592/phco.20.4.318.34881</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Byon</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Garonzik</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Boyd</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Frost</surname><given-names>CE</given-names></string-name></person-group>. <article-title>Apixaban: a clinical pharmacokinetic and pharmacodynamic review</article-title>. <source>Clin Pharmacokinet</source>. <year>2019</year>;<volume>58</volume>(<issue>10</issue>):<fpage>1265</fpage>&#8211;<lpage>79</lpage>.<pub-id pub-id-type="pmid">31089975</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40262-019-00775-z</pub-id><pub-id pub-id-type="pmcid">PMC6769096</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Frost</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Garonzik</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Shenker</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Barrett</surname><given-names>YC</given-names></string-name>, <string-name name-style="western"><surname>LaCreta</surname><given-names>F</given-names></string-name></person-group>. <article-title>Apixaban single&#8208;dose pharmacokinetics, bioavailability, renal clearance, and pharmacodynamics following intravenous and oral administration</article-title>. <source>Clin Pharmacol Drug Dev</source>. <year>2021</year>;<volume>10</volume>(<issue>9</issue>):<fpage>974</fpage>&#8211;<lpage>84</lpage>.<pub-id pub-id-type="pmid">34342172</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpdd.990</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nolen</surname><given-names>WA</given-names></string-name>, <string-name name-style="western"><surname>Jansen</surname><given-names>GS</given-names></string-name>, <string-name name-style="western"><surname>Broekman</surname><given-names>M</given-names></string-name></person-group>. <article-title>Measuring plasma levels of carbamazepine. A pharmacokinetic study in patients with affective disorders</article-title>. <source>Pharmacopsychiatry</source>. <year>1988</year>;<volume>21</volume>(<issue>5</issue>):<fpage>252</fpage>&#8211;<lpage>4</lpage>.<pub-id pub-id-type="pmid">3227056</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/s-2007-1016965</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rawlins</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Collste</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Bertilsson</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Palm&#233;r</surname><given-names>L</given-names></string-name></person-group>. <article-title>Distribution and elimination kinetics of carbamazepine in man</article-title>. <source>Eur J Clin Pharmacol</source>. <year>1975</year>;<volume>8</volume>(<issue>2</issue>):<fpage>91</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">1233212</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00561556</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chong</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Dupuis</surname><given-names>LL</given-names></string-name></person-group>. <article-title>Therapeutic drug monitoring of lamotrigine</article-title>. <source>Ann Pharmacother</source>. <year>2002</year>;<volume>36</volume>(<issue>5</issue>):<fpage>917</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="pmid">11978172</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1345/aph.1A252</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Methaneethorn</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Leelakanok</surname><given-names>N</given-names></string-name></person-group>. <article-title>Sources of lamotrigine pharmacokinetic variability: a systematic review of population pharmacokinetic analyses</article-title>. <source>Seizure</source>. <year>2020</year>;<volume>82</volume>:<fpage>133</fpage>&#8211;<lpage>47</lpage>.<pub-id pub-id-type="pmid">33060011</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.seizure.2020.07.014</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>May</surname><given-names>TW</given-names></string-name>, <string-name name-style="western"><surname>Korn-Merker</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Rambeck</surname><given-names>B</given-names></string-name></person-group>. <article-title>Clinical pharmacokinetics of oxcarbazepine</article-title>. <source>Clin Pharmacokinet</source>. <year>2003</year>;<volume>42</volume>(<issue>12</issue>):<fpage>1023</fpage>&#8211;<lpage>42</lpage>.<pub-id pub-id-type="pmid">12959634</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00003088-200342120-00002</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Greenberg</surname><given-names>RG</given-names></string-name>, <string-name name-style="western"><surname>Melloni</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Gonzalez</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ku</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Hill</surname><given-names>KD</given-names></string-name>, <etal/></person-group>. <article-title>Therapeutic index estimation of antiepileptic drugs: a systematic literature review approach</article-title>. <source>Clin Neuropharm</source>. <year>2016</year>;<volume>39</volume>(<issue>5</issue>):<fpage>232</fpage>&#8211;<lpage>40</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/WNF.0000000000000172</pub-id><pub-id pub-id-type="pmcid">PMC5026556</pub-id><pub-id pub-id-type="pmid">27428884</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bergen</surname><given-names>DC</given-names></string-name></person-group>. <article-title>Pharmacokinetics of phenytoin: reminders and discoveries</article-title>. <source>Epilepsy Curr</source>. <year>2009</year>;<volume>9</volume>(<issue>4</issue>):<fpage>102</fpage>&#8211;<lpage>4</lpage>.<pub-id pub-id-type="pmid">19693326</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1535-7511.2009.01307.x</pub-id><pub-id pub-id-type="pmcid">PMC2728486</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gugler</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>von Unruh</surname><given-names>GE</given-names></string-name></person-group>. <article-title>Clinical pharmacokinetics of valproic acid</article-title>. <source>Clin Pharmacokinet</source>. <year>1980</year>;<volume>5</volume>(<issue>1</issue>):<fpage>67</fpage>&#8211;<lpage>83</lpage>.<pub-id pub-id-type="pmid">6767575</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00003088-198005010-00002</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jonsson</surname><given-names>EN</given-names></string-name>, <string-name name-style="western"><surname>Antila</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>McFadyen</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Lehtonen</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Karlsson</surname><given-names>MO</given-names></string-name></person-group>. <article-title>Population pharmacokinetics of levosimendan in patients with congestive heart failure</article-title>. <source>Br J Clin Pharmacol</source>. <year>2003</year>;<volume>55</volume>(<issue>6</issue>):<fpage>544</fpage>&#8211;<lpage>51</lpage>.<pub-id pub-id-type="pmid">12814448</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1365-2125.2003.01778.x</pub-id><pub-id pub-id-type="pmcid">PMC1884248</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Grze&#347;k</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Wo&#322;owiec</surname><given-names>&#321;</given-names></string-name>, <string-name name-style="western"><surname>Rogowicz</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Gilewski</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Kowalkowska</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Banach</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>The importance of pharmacokinetics, pharmacodynamic and repetitive use of levosimendan</article-title>. <source>Biomed Pharmacother</source>. <year>2022</year>;<volume>153</volume>:<fpage>113391</fpage>.<pub-id pub-id-type="pmid">36076524</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2022.113391</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kajbaf</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>De Broe</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Lalau</surname><given-names>J-D</given-names></string-name></person-group>. <article-title>Therapeutic concentrations of metformin: a systematic review</article-title>. <source>Clin Pharmacokinet</source>. <year>2016</year>;<volume>55</volume>(<issue>4</issue>):<fpage>439</fpage>&#8211;<lpage>59</lpage>.<pub-id pub-id-type="pmid">26330026</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40262-015-0323-x</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jeong</surname><given-names>Y-S</given-names></string-name>, <string-name name-style="western"><surname>Jusko</surname><given-names>WJ</given-names></string-name></person-group>. <article-title>Meta-assessment of metformin absorption and disposition pharmacokinetics in nine species</article-title>. <source>Pharmaceuticals</source>. <year>2021</year>;<volume>14</volume>(<issue>6</issue>):<fpage>545</fpage>.<pub-id pub-id-type="pmid">34200427</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ph14060545</pub-id><pub-id pub-id-type="pmcid">PMC8226464</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ginimuge</surname><given-names>PR</given-names></string-name>, <string-name name-style="western"><surname>Jyothi</surname><given-names>SD</given-names></string-name></person-group>. <article-title>Methylene blue: revisited</article-title>. <source>J Anaesthesiol Clin Pharmacol</source>. <year>2010</year>;<volume>26</volume>(<issue>4</issue>):<fpage>517</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="pmid">21547182</pub-id><pub-id pub-id-type="pmcid">PMC3087269</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Peter</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hongwan</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>K&#252;pfer</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Lauterburg</surname><given-names>BH</given-names></string-name></person-group>. <article-title>Pharmacokinetics and organ distribution of intravenous and oral methylene blue</article-title>. <source>Eur J Clin Pharmacol</source>. <year>2000</year>;<volume>56</volume>(<issue>3</issue>):<fpage>247</fpage>&#8211;<lpage>50</lpage>.<pub-id pub-id-type="pmid">10952480</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s002280000124</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Disanto</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Wagner</surname><given-names>JG</given-names></string-name></person-group>. <article-title>Pharmacokinetics of highly ionized drugs III: methylene blue&#8212;blood levels in the dog and tissue levels in the rat following intravenous administration</article-title>. <source>J Pharm Sci</source>. <year>1972</year>;<volume>61</volume>(<issue>7</issue>):<fpage>1090</fpage>&#8211;<lpage>4</lpage>.<pub-id pub-id-type="pmid">5044808</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jps.2600610711</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Thanacoody</surname><given-names>RHK</given-names></string-name></person-group>. <article-title>Extracorporeal elimination in acute valproic acid poisoning</article-title>. <source>Clin Toxicol</source>. <year>2009</year>;<volume>47</volume>(<issue>7</issue>):<fpage>609</fpage>&#8211;<lpage>16</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/15563650903167772</pub-id><pub-id pub-id-type="pmid">19656009</pub-id></mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nguyen</surname><given-names>H-L</given-names></string-name>, <string-name name-style="western"><surname>Concepcion</surname><given-names>L</given-names></string-name></person-group>. <article-title>Metformin intoxication requiring dialysis</article-title>. <source>Hemodial Int</source>. <year>2011</year>;<volume>15</volume>(<issue>Suppl 1</issue>):<fpage>S68</fpage>&#8211;<lpage>71</lpage>.<pub-id pub-id-type="pmid">22093605</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1542-4758.2011.00605.x</pub-id></mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Leonaviciute</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Madsen</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Schmedes</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Buus</surname><given-names>NH</given-names></string-name>, <string-name name-style="western"><surname>Rasmussen</surname><given-names>BS</given-names></string-name></person-group>. <article-title>Severe metformin poisoning successfully treated with simultaneous venovenous hemofiltration and prolonged intermittent hemodialysis</article-title>. <source>Case Rep Crit Care</source>. <year>2018</year>;<volume>2018</volume>(<issue>1</issue>):<fpage>3868051</fpage>.<pub-id pub-id-type="pmid">29854476</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2018/3868051</pub-id><pub-id pub-id-type="pmcid">PMC5964555</pub-id></mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Barrueto</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Meggs</surname><given-names>WJ</given-names></string-name>, <string-name name-style="western"><surname>Barchman</surname><given-names>MJ</given-names></string-name></person-group>. <article-title>Clearance of metformin by hemofiltration in overdose</article-title>. <source>J Toxicol Clin Toxicol</source>. <year>2002</year>;<volume>40</volume>(<issue>2</issue>):<fpage>177</fpage>&#8211;<lpage>80</lpage>.<pub-id pub-id-type="pmid">12126190</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1081/clt-120004407</pub-id></mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mitrovic</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Huntjens</surname><given-names>DW</given-names></string-name>, <string-name name-style="western"><surname>de Vos</surname><given-names>EAJ</given-names></string-name>, <string-name name-style="western"><surname>van Tellingen</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Franssen</surname><given-names>EJF</given-names></string-name></person-group>. <article-title>Extracorporeal hemoadsorption with the CytoSorb device as a potential therapeutic option in severe intoxications: review of the rationale and current clinical experiences</article-title>. <source>J Clin Pharm Ther</source>. <year>2022</year>;<volume>47</volume>(<issue>9</issue>):<fpage>1444</fpage>&#8211;<lpage>51</lpage>.<pub-id pub-id-type="pmid">35924306</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jcpt.13724</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>